Protein kinase A-mediated phosphorylation of RhoA on serine 188 triggers the rapid induction of a neuroendocrine-like phenotype in prostate cancer epithelial cells
详细信息 查看全文
- 作者：Sarah E. Jones <sup>Sarah.Jones.2@glasgow.ac.uksup> ; Timothy M. Palmer<sup> ; sup><sup>Tim.Palmer@glasgow.ac.uksup>
- 关键词：PCa ; prostate cancer ; cAMP ; cyclic AMP ; NE ; neuroendocrine ; PSA ; prostate-specific antigen ; PKA ; cAMP-dependent protein kinase ; bFGF ; basic fibroblast growth factor ; NGF ; nerve growth factor ; 6-Bnz-cAMP ; N6-benzoyl-cAMP ; Fsk ; forskolin ; C3T ; cell-permeabl
- 刊名：Cellular Signalling
- 出版年：2012
- 出版时间：August, 2012
- 年：2012
- 卷：24
- 期：8
- 页码：1504-1514
- 全文大小：2674 K
文摘
Whilst androgen ablation therapy is used to treat locally advanced or metastatic forms of prostate cancer, side-effects can include the emergence of an androgen-independent neuroendocrine cell population which is associated with poor prognosis. Here we have examined how cyclic AMP elevation regulates early events in the neuroendocrine differentiation process. We demonstrate that selective activation of protein kinase A is necessary and sufficient for cyclic AMP (cAMP) elevation to rapidly promote a neuroendocrine phenotype in LNCaP cells independent of de novo protein synthesis. Furthermore, the effects of cAMP could be recapitulated by inhibition of RhoA signalling or pharmacological inhibition of Rho kinase. Conversely, expression of constitutively active Gln63Leu-mutated RhoA acted as a dominant-negative inhibitor of cAMP-mediated NE phenotype formation. Consistent with these observations, cAMP elevation triggered the PKA-dependent phosphorylation of RhoA on serine 188, and a non-phosphorylatable Ser188Ala RhoA mutant functioned as a dominant-negative inhibitor of cAMP-mediated neuroendocrine phenotype formation. These results suggest that PKA-mediated inhibition of RhoA via its phosphorylation on serine 188 and the subsequent inhibition of ROCK activity plays a key role in determining initial changes in cellular morphology during LNCaP cell differentiation to a neuroendocrine phenotype. It also raises the possibility that targeted suppression of this pathway to inhibit neuroendocrine cell expansion might be a useful adjuvant to conventional prostate cancer therapy.